Device Trial Radar · NCT03214627
Artificial Intelligence for Optimal Anemia Management in End-stage Renal Disease: The Anemia Control Model (ACM) Trial
Last checked: Nov 20, 2026Latest source record: Jan 7, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
88
Actual
Start
Dec 10, 2018
Primary completion
May 21, 2019
Study completion May 21, 2019
Sponsor
- Lead sponsor
- Vifor Fresenius Medical Care Renal PharmaNot on our public-company list
- Sponsor type
- Industry
- Collaborators
- Worldwide Clinical Trials; Fresenius Medical Care Deutschland GmbH
- First posted
- Jul 11, 2017
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Other
- FDA-regulated device
- No
- Who can join
- All sexes, from 19 years, up to 90 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Fresenius Medical Care has developed a computer software programme called the Anaemia Control Management (ACM) software to assist in the anaemia management of patients with chronic kidney disease (CKD) undergoing hemodialysis. This trial is designed to assess the effectiveness of this ACM software on anaemia management in routine clinical practice. However, all ultimate decisions on therapeutic or diagnostic procedures, treatments, management of the disease, or resource utilisation will be at the discretion of the Investigator. The trial consists of a retrospective (historical) control period and a prospective (going forward) period. During the prospective period, the ACM will be used to assist the Investigators' decision making and will help the Investigators to administer a personalised intravenous (IV) iron and red blood cell stimulating agent (ESA) therapy, whereas treatment according to standard of care will be documented retrospectively for the same patients during the retrospective period of the trial. Thus, patients can serve as their own control.
Conditions
- Anemia
- End Stage Renal Disease
Interventions
Anemia Control Model (ACM)Device
The ACM is mainly composed of 2 sub-Systems - predictor model which, depending on the input data, forecasts the response to anaemia drug therapy for a specific patient. The predictor model is implemented as a feed-forward artificial neural network. The ACM is an algorithm that extracts the optimal policy to achieve the established clinical outcome for anaemia management using the predictor model.
IV ironDrug
IV iron given monthly as required - dose determined by the ACM and as agreed by the investigator
Erythropoiesis-Stimulating Agent (ESA)Drug
ESA given monthly as required over 6 months - dose determined by the ACM and as agreed by the investigator
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in the proportion of patients with haemoglobin within the target range as compared to the historical control period (non-inferiority testing)Time frame: Month -6 to Month -1 compared with Month +1 to Month +6
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Kings College Hospital
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.